Tetracycline and its analogues protect Caenorhabditis elegans from β amyloid-induced toxicity by targeting oligomers

Neurobiology of Disease
Luisa DiomedeMario Salmona

Abstract

The accumulation and deposition of amyloid beta (Aβ) peptide in extracellular dense plaques in the brain is a key phase in Alzheimer's disease (AD). Small oligomeric forms of Aβ are responsible for the toxicity and the early cognitive impairment observed in patients before the amyloid plaque deposits appear. It is essential for the development of an efficient cure for AD to identify compounds that interfere with Aβ aggregation, counteracting the molecular mechanisms involved in conversion of the monomeric amyloid protein into oligomeric and fibrillar forms. Tetracyclines have been proposed for AD therapy, although their effects on the aggregation of Aβ protein, particularly their ability to interact in vivo with the Aβ oligomers and/or aggregates, remain to be understood. Using transgenic Caenorhabditis elegans as a simplified invertebrate model of AD, we evaluated the ability of tetracyclines to interfere with the sequence of events leading to Aβ proteotoxicity. The drugs directly interact with the Aβ assemblies in vivo and reduce Aβ oligomer deposition, protecting C. elegans from oxidative stress and the onset of the paralysis phenotype. These effects were specific, dose-related and not linked to any antibiotic activity, sugg...Continue Reading

References

May 2, 2003·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Isabel CardosoMaria João Saraiva
Nov 26, 2003·Biochimica Et Biophysica Acta·Janina KneippDieter Naumann
Apr 7, 2005·Genes, Brain, and Behavior·C D Link
Nov 2, 2006·Journal of Neurochemistry·Todd E Golde
Apr 5, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Yoori ChoiYoo-Hun Suh
Oct 6, 2007·Biochimica Et Biophysica Acta·Diletta AmiCarlo Alberto Redi
Oct 17, 2007·Chembiochem : a European Journal of Chemical Biology·Manuela BartoliniVincenza Andrisano
Oct 24, 2007·ChemMedChem·Cliff I StainsIndraneel Ghosh
Dec 29, 2007·British Journal of Haematology·Ashutosh D WechalekarJulian D Gillmore
Aug 12, 2008·Current Alzheimer Research·Robert E Becker, Nigel H Greig
Sep 6, 2008·Molecular Neurobiology·Daniela L RebolledoNibaldo C Inestrosa
Feb 10, 2009·Infectious Disorders Drug Targets·Gianluigi ForloniFabrizio Tagliavini

❮ Previous
Next ❯

Citations

Apr 25, 2013·Journal of Medicinal Chemistry·Tatiana StoilovaMario Salmona
Jan 7, 2011·Metallomics : Integrated Biometal Science·Ebany J Martinez-FinleyMichael Aschner
Nov 12, 2010·The Journal of Biological Chemistry·Sofia GiorgettiMonica Stoppini
Oct 15, 2011·The Journal of Biological Chemistry·Rita CostaIsabel Cardoso
Nov 23, 2013·The Journal of Infectious Diseases·Samia HannaouiStéphane Haïk
Mar 3, 2012·Cellular and Molecular Life Sciences : CMLS·Márcio S BaptistaPatrícia Maciel
Feb 18, 2016·Cellular and Molecular Neurobiology·Weimin ZhangHongyu Li
Jun 6, 2013·Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis·Giovanni MontagnaVittorio Bellotti
Aug 14, 2012·Luminescence : the Journal of Biological and Chemical Luminescence·Aleksandra KładnaHassan Y Aboul-Enein
Mar 12, 2017·Journal of Alzheimer's Disease : JAD·Margherita RomeoLuisa Diomede
Mar 13, 2015·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Irene SolaDiego Muñoz-Torrero
Jan 12, 2013·Dementia and Geriatric Cognitive Disorders·Brian S ApplebyJeffrey L Cummings
May 31, 2018·Journal of Alzheimer's Disease : JAD·Erika N ClineWilliam L Klein
Dec 15, 2010·Biotechnology Journal·Maria Markaki, Nektarios Tavernarakis
Apr 25, 2019·International Journal of Molecular Sciences·Thais A SalesTeodorico C Ramalho
Jan 10, 2012·Aging Cell·Silvestre Alavez, Gordon J Lithgow
Nov 7, 2018·The Journal of Pharmacology and Experimental Therapeutics·Jacopo LucchettiMarco Gobbi
Sep 25, 2019·International Journal of Molecular Sciences·Alfonso GautieriMario Salmona
Nov 11, 2011·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Monica BucciantiniMassimo Stefani
Feb 25, 2019·Neurotoxicity Research·Flávia Viana Santa-CecíliaRita Raisman-Vozari
Jul 25, 2019·Frontiers in Pharmacology·Claudia Balducci, Gianluigi Forloni
May 13, 2018·Pharmaceuticals·Fernando DurãesEmília Sousa
Nov 10, 2020·Neuroscience Letters·Xiaochen SongNing Xie

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthelmintics (ASM)

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.